KNSA - Kiniksa Pharmaceuticals, Ltd.
IEX Last Trade
20.05
0.130 0.648%
Share volume: 20,314
Last Updated: Fri 27 Dec 2024 08:30:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$19.92
0.13
0.65%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-03-02 | 2023-05-04 | 2023-08-01 | 2023-11-02 | 2024-02-28 | 2024-04-25 | |
| Assets | |||||||||
| Total Assets | 210.576 M | 459.953 M | 459.672 M | 442.862 M | 484.332 M | 483.063 M | 526.322 M | 519.673 M | |
| Current Assets | 179.938 M | 241.815 M | 243.060 M | 231.500 M | 246.040 M | 256.109 M | 276.297 M | 270.591 M | |
| Inventories | 19.916 M | 14.621 M | 21.599 M | 23.425 M | 23.958 M | 25.583 M | 31.122 M | 27.278 M | |
| Other Current Assets | 14.006 M | 15.311 M | 18.193 M | 13.157 M | 12.440 M | 26.401 M | 17.538 M | 13.766 M | |
| Short Term Investments | 14.006 M | 15.311 M | 18.193 M | 13.157 M | 12.440 M | 26.401 M | 17.538 M | 13.766 M | |
| Total Receivables | 7.808 M | 11.159 M | 12.660 M | 7.424 M | 24.650 M | 3.041 M | 21.266 M | 15.995 M | |
| Current Cash | 138.208 M | 200.724 M | 190.608 M | 187.494 M | 184.992 M | 201.084 M | 206.371 M | 213.552 M | |
| Total Non-current Assets | 30.638 M | 218.138 M | 216.612 M | 211.362 M | 238.292 M | 226.954 M | 250.025 M | 249.082 M | |
| Property Plant Equipment | 2.150 M | 1.995 M | 1.658 M | 1.393 M | 1.136 M | 918.000 K | 734.000 K | 712.000 K | |
| Other Assets | 9.738 M | 11.800 M | 11.209 M | 7.551 M | 15.544 M | 14.962 M | 12.758 M | 16.452 M | |
| Intangible Assets | 18.750 M | 18.500 M | 18.250 M | 18.000 M | 17.750 M | 17.500 M | 17.250 M | 17.000 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 210.576 M | 459.953 M | 459.672 M | 442.862 M | 484.332 M | 483.063 M | 526.322 M | 519.673 M | |
| Total liabilities | 57.082 M | 75.945 M | 63.523 M | 52.767 M | 72.676 M | 77.936 M | 87.483 M | 87.778 M | |
| Total current liabilities | 43.544 M | 56.492 M | 47.066 M | 36.587 M | 47.472 M | 53.468 M | 63.666 M | 64.212 M | |
| Accounts Payable | 2.522 M | 1.469 M | 7.899 M | 1.391 M | 648.000 K | 1.012 M | 8.246 M | 5.632 M | |
| Other liabilities | 12.260 M | 16.018 M | 13.839 M | 14.047 M | 13.921 M | 13.817 M | 13.812 M | 13.702 M | |
| Current long term debt | 3.336 M | 3.274 M | 3.301 M | 3.482 M | 2.238 M | 2.313 M | 2.253 M | 2.279 M | |
| Long term debt | 1.278 M | 3.435 M | 2.618 M | 2.133 M | 11.283 M | 10.651 M | 10.005 M | 9.864 M | |
| Other liabilities | 12.260 M | 16.018 M | 13.839 M | 14.047 M | 13.921 M | 13.817 M | 13.812 M | 13.702 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 153.494 M | 384.008 M | 396.149 M | 390.095 M | 411.656 M | 405.127 M | 438.839 M | 431.895 M | |
| Common stock | 69.290 M | 69.445 M | 69.657 M | 69.752 M | 69.918 M | 70.186 M | 70.380 M | 70.633 M | |
| Retained earnings | -720.588 M | -496.495 M | -492.034 M | -504.304 M | -489.332 M | -503.187 M | -477.950 M | -495.654 M |